Form ABS-EE Exeter Automobile Receiv For: Feb 29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM FOR SUBMISSION OF ELECTRONIC EXHIBITS FOR
ASSET-BACKED SECURITIES
Commission File Number of the issuing entity: 333-233850-04
Central Index Key Number of the issuing entity: 0001876620
Exeter Automobile Receivables Trust 2021-3
(Exact name of issuing entity as specified in its charter)
Commission File Number of the depositor: 333-233850
Central Index Key Number of the depositor: 0001654238
EFCAR, LLC
(Exact name of depositor as specified in its charter)
Central Index Key Number of sponsor (if applicable): 0001541713
Exeter Finance LLC
(Exact name of sponsor as specified in its charter)
Jodi Blanton, (469) 754-4396
(Name and telephone number, including area code, of the person to contact in connection with this filing)
INFORMATION INCLUDED WITH THIS FORM
| Item 1. |
The Asset Data File required to be filed in accordance with Exhibit 601(b)(102) (17 CFR 229.601(b)(102)) is attached as Exhibit 102 to this Form ABS-EE.
|
| Item 2. |
The Asset Related Document required to be filed in accordance with Exhibit 601(b)(103) (17 CFR 229.601(b)(103)) is attached as Exhibit 103 to this Form ABS-EE.
|
EXHIBIT INDEX
| Exhibit 102 |
Asset Data File
|
| Exhibit 103 |
Asset Related Document (Additional Explanatory Disclosure)
|
SIGNATURES
The depositor has duly caused this Form to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 27, 2024
EXETER AUTOMOBILE RECEIVABLES TRUST 2021-3
(Issuing Entity)
By: Exeter Finance LLC, as Servicer
By: /s/ Jeff Briggs
Name: Jeff Briggs
Title: Senior Vice President and Assistant Treasurer
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress
- ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
- Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share